An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge

Vaccine ◽  
2012 ◽  
Vol 30 (21) ◽  
pp. 3202-3208 ◽  
Author(s):  
Natalie A. Hutnick ◽  
Devin J.F. Myles ◽  
Lauren Hirao ◽  
Veronica L. Scott ◽  
Bernadette Ferraro ◽  
...  
Keyword(s):  
Dna Vaccine ◽  
High Dose ◽  
Partial Protection ◽  
Sivmac251 Challenge

Partial protection against streptozotocin-induced hyperglycaemia by superoxide dismutase linked to polyethylene glycol

1984 ◽  
Vol 107 (3) ◽  
pp. 390-394 ◽  
Author(s):  
kjell Asplund ◽  
Kjell Grankvist ◽  
Stefan Marklund ◽  
Inge-Bert Täljedal
Keyword(s):  
Superoxide Dismutase ◽  
Polyethylene Glycol ◽  
Blood Glucose ◽  
Superoxide Radicals ◽  
High Dose ◽  
Partial Protection ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Pre Treatment

Abstract. To test the possible role of superoxide radicals in the diabetogenic action of streptozotocin, blood glucose levels were measured in mice after a single high-dose (150 mg/kg body weight) or multiple low-dose (40 mg/kg for 5 days) injections of streptozotocin. Pre-treatment 6 h before streptozotocin with 250–300 mg/kg superoxide dismutase coupled to polyethylene glycol reduced the hyperglycaemic response in mice injected with a single dose of streptozotocin. The blood glucose levels after multiple low doses of streptozotocin were not affected by superoxide dismutase-polvethvlene glycol. Enzymatically inactive superoxide dismutase did not affect the development of hyperglycaemia. The results suggest that superoxide radicals may play a role in the diabetogenic action of streptozotocin injected as a high-dose single bolus.

scholarly journals Anti-CoVid19 plasmid DNA vaccine induces a potent immune response in rodents by Pyro-drive Jet Injector intradermal inoculation

2021 ◽  
Author(s):  
Tomoyuki Nishikawa ◽  
Chin Yang Chang ◽  
Jiayu A Tai ◽  
Hiroki Hayashi ◽  
Jiao Sun ◽  
...  
Keyword(s):  
Dna Vaccine ◽  
Plasmid Dna ◽  
Injection Pressure ◽  
Intradermal Injection ◽  
High Dose ◽  
Injection Device ◽  
Short Term ◽  
S Protein ◽  
Plasmid Dna Vaccine ◽  
Potent Immune Response

There is an urgent need to limit and stop the worldwide coronavirus disease 2019 (COVID-19) pandemic via quick development of efficient and safe vaccination methods. Plasmid DNA vaccines are one of the most remarkable vaccines that can be developed in a short term. pVAX1-SARS-CoV2-co, which is a plasmid DNA vaccine, was designed to express severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. The produced antibodies lead to Immunoreactions against S protein, anti-receptor-binding-domain, and neutralizing action of pVAX1-SARS-CoV2-co, as confirmed in a previous study. To promote the efficacy of the pVAX1-SARS-CoV2-co vaccine, a pyro-drive jet injector (PJI) was employed. PJI is an injection device that can adjust the injection pressure depending on various target tissues. Intradermally-adjusted PJI demonstrated that pVAX1-SARS-CoV2-co vaccine injection caused a strong production of anti-S protein antibodies, triggered immunoreactions and neutralizing actions against SARS-CoV-2. Moreover, a high dose of pVAX1-SARS-CoV2-co intradermal injection via PJI did not cause any serious disorders in the rat model. Finally, virus infection challenge in mice, confirmed that intradermally immunized (via PJI) mice were potently protected from COVID-19 infection. Thus, pVAX1-SARS-CoV2-co intradermal injection via PJI is a safe and promising vaccination method to overcome the COVID-19 pandemic.

Vaccination of mice with DNA vaccine induces the immune response and partial protection against T. spiralis infection

Vaccine ◽  
2006 ◽  
Vol 24 (8) ◽  
pp. 1205-1212 ◽  
Author(s):  
Z WANG ◽  
J CUI ◽  
H WEI ◽  
H HAN ◽  
H ZHANG ◽  
...  
Keyword(s):  
Immune Response ◽  
Dna Vaccine ◽  
Partial Protection

scholarly journals A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge

Vaccine ◽  
2011 ◽  
Vol 29 (39) ◽  
pp. 6755-6762 ◽  
Author(s):  
Devon J. Shedlock ◽  
Kendra T. Talbott ◽  
Christina Cress ◽  
Bernadette Ferraro ◽  
Steven Tuyishme ◽  
...  
Keyword(s):  
Dna Vaccine ◽  
Protective Immunity ◽  
Lymphocytic Choriomeningitis ◽  
Lymphocytic Choriomeningitis Virus ◽  
High Dose ◽  
Virus Challenge

A DNA VACCINE EXPRESSINGENVANDGAGOFFERS PARTIAL PROTECTION AGAINST RETICULOENDOTHELIOSIS VIRUS IN THE PRAIRIE CHICKEN (TYMPANICUS CUPIDO)

2013 ◽  
Vol 44 (2) ◽  
pp. 251-261 ◽  
Author(s):  
Yvonne Drechsler ◽  
Suzana Tkalcic ◽  
Miguel D. Saggese ◽  
H. L. Shivaprasad ◽  
Dharani K. Ajithdoss ◽  
...  
Keyword(s):  
Dna Vaccine ◽  
Reticuloendotheliosis Virus ◽  
Partial Protection ◽  
Prairie Chicken

scholarly journals A DNA Vaccine Formulated with Chemical Adjuvant Provides Partial Protection against Bovine Herpes Virus Infection in Cattle

2017 ◽  
Vol 8 ◽  
Author(s):  
Valeria Quattrocchi ◽  
Ivana Soria ◽  
Cecilia Ana Langellotti ◽  
Victoria Gnazzo ◽  
Mariela Gammella ◽  
...  
Keyword(s):  
Virus Infection ◽  
Dna Vaccine ◽  
Herpes Virus ◽  
Herpes Virus Infection ◽  
Partial Protection ◽  
Herpès Virus

scholarly journals 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate

2011 ◽  
Vol 300 (4) ◽  
pp. E650-E660 ◽  
Author(s):  
Joshua F. Yarrow ◽  
Christine F. Conover ◽  
Sean C. McCoy ◽  
Judyta A. Lipinska ◽  
Cesar A. Santillana ◽  
...  
Keyword(s):  
Bone Loss ◽  
Visceral Fat ◽  
Levator Ani ◽  
High Dose ◽  
Testosterone Enanthate ◽  
Mineral Density ◽  
Trabecular Bone Mineral Density ◽  
Partial Protection ◽  
Fat Accumulation ◽  
Visceral Fat Accumulation

Selective androgen receptor modulators (SARMs) now under development can protect against muscle and bone loss without causing prostate growth or polycythemia. 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone), a potent testosterone analog, may have SARM-like actions because, unlike testosterone, trenbolone does not undergo tissue-specific 5α-reduction to form more potent androgens. We tested the hypothesis that trenbolone-enanthate (TREN) might prevent orchiectomy-induced losses in muscle and bone and visceral fat accumulation without increasing prostate mass or resulting in adverse hemoglobin elevations. Male F344 rats aged 3 mo underwent orchiectomy or remained intact and were administered graded doses of TREN, supraphysiological testosterone-enanthate, or vehicle for 29 days. In both intact and orchiectomized animals, all TREN doses and supraphysiological testosterone-enanthate augmented androgen-sensitive levator ani/bulbocavernosus muscle mass by 35–40% above shams ( P ≤ 0.001) and produced a dose-dependent partial protection against orchiectomy-induced total and trabecular bone mineral density losses ( P < 0.05) and visceral fat accumulation ( P < 0.05). The lowest doses of TREN successfully maintained prostate mass and hemoglobin concentrations at sham levels in both intact and orchiectomized animals, whereas supraphysiological testosterone-enanthate and high-dose TREN elevated prostate mass by 84 and 68%, respectively ( P < 0.01). In summary, low-dose administration of the non-5α-reducible androgen TREN maintains prostate mass and hemoglobin concentrations near the level of shams while producing potent myotrophic actions in skeletal muscle and partial protection against orchiectomy-induced bone loss and visceral fat accumulation. Our findings indicate that TREN has advantages over supraphysiological testosterone and supports the need for future preclinical studies examining the viability of TREN as an option for androgen replacement therapy.

Sign in / Sign up

Export Citation Format

Share Document